Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.
Brinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, Gingras G, Ghasriani H, Aubin Y, Pierens GK, Jia X, Mobli M, Grant HG, Keizer DW, Schweimer K, Ståhle J, Widmalm G, Zartler ER, Lawrence CW, Reardon PN, Cort JR, Xu P, Ni F, Yanaka S, Kato K, Parnham SR, Tsao D, Blomgren A, Rundlöf T, Trieloff N, Schmieder P, Ross A, Skidmore K, Chen K, Keire D, Freedberg DI, Suter-Stahel T, Wider G, Ilc G, Plavec J, Bradley SA, Baldisseri DM, Sforça ML, Zeri ACM, Wei JY, Szabo CM, Amezcua CA, Jordan JB, Wikström M.
Brinson RG, et al. Among authors: zeri acm.
MAbs. 2019 Jan;11(1):94-105. doi: 10.1080/19420862.2018.1544454. Epub 2018 Dec 22.
MAbs. 2019.
PMID: 30570405
Free PMC article.